MALIGHETTI FEDERICA

Malighetti, F., Civettini, I., Aroldi, A., Villa, A., Villa, M., Sala, L., et al. (2026). Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations. BIOINFORMATICS, 42(Supplement_2) [10.1093/bioinformatics/btag491]. Dettaglio

Civettini, I., Malighetti, F., Villa, M., Crippa, V., Aroldi, A., Cavalca, F., et al. (2026). Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution. NEJM EVIDENCE, 5(6), 1-13 [10.1056/evidoa2500124]. Dettaglio

Villa, M., Malighetti, F., Villa, A., Cordani, N., Aroldi, A., Zambon, A., et al. (2026). Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. JOURNAL OF TRANSLATIONAL MEDICINE [10.1186/s12967-026-08420-7]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio

Villa, M., Cazzaniga, G., Bolognesi, M., Malighetti, F., Crippa, V., Aroldi, A., et al. (2025). Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers. HELIYON, 11(12 (July 2025)) [10.1016/j.heliyon.2025.e43533]. Dettaglio